1. A phase I/II dose finding study evaluating the safety and tolerability of capecitabine and aflibercept in patients with unresectable metastatic colorectal cancer deemed unsuitable for doublet/triplet chemotherapy: results of the phase I study. (February 2017) Authors: Ross, P.J.; Repana, D.; Saunders, M.; Wilson, R.H.; Plummer, C.J.; Summers, J.; Higgins, F.; Peacock, J.; Harari, D.; Bridgewater, J. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical outcomes for patients with liver-limited metastatic colorectal cancer: Arguing the case for specialist hepatobiliary multidisciplinary assessment. Issue 9 (September 2016) Authors: Thillai, K.; Repana, D.; Korantzis, I.; Kane, P.; Prachalias, A.; Ross, P. Journal: European journal of surgical oncology Issue: Volume 42:Issue 9(2016:Sep.) Page Start: 1331 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗